Bortezomib-induced peripheral neurotoxicity: an update

This review paper provides a critical exploration of updates concerning the spectrum of characteristics and treatment options of bortezomib-induced peripheral neuropathy (BIPN). Emphasis is given on pathogenesis issues. Although the mechanism underlying BIPN still remains elusive, it is increasingly...

Descripción completa

Detalles Bibliográficos
Autores: Argyriou, Andreas A., Cavaletti, Guido, Bruna, Jordi, Kyritsis, Athanasios P., Kalofonos, Haralabos P.
Tipo de recurso: artículo
Estado:Versión aceptada para publicación
Fecha de publicación:2014
País:España
Institución:Universidad de Barcelona
Repositorio:Dipòsit Digital de la UB
OAI Identifier:oai:diposit.ub.edu:2445/222979
Acceso en línea:https://hdl.handle.net/2445/222979
Access Level:acceso abierto
Palabra clave:Neuropaties perifèriques
Malalties neurocutànies
Peripheral neuropathies
Neurocutaneous disorders
id ES_cd5eac7a4d30339e808fdfbe3ca2ef81
oai_identifier_str oai:diposit.ub.edu:2445/222979
network_acronym_str ES
network_name_str España
repository_id_str
spelling Bortezomib-induced peripheral neurotoxicity: an updateArgyriou, Andreas A.Cavaletti, GuidoBruna, JordiKyritsis, Athanasios P.Kalofonos, Haralabos P.Neuropaties perifèriquesMalalties neurocutàniesPeripheral neuropathiesNeurocutaneous disordersThis review paper provides a critical exploration of updates concerning the spectrum of characteristics and treatment options of bortezomib-induced peripheral neuropathy (BIPN). Emphasis is given on pathogenesis issues. Although the mechanism underlying BIPN still remains elusive, it is increasingly acknowledged that the inhibition of proteasome activity in dorsal root ganglia and peripheral nerves, the mitochondrial-mediated disruption of Ca++ intracellular homeostasis and the disregulation in nuclear factor kappa B and brain-derived neurotrophic factor play a significant pathogenic role. Assessment of BIPN is based on comprehensive grading scales, using a combination of "subjective" and "objective" parameters, which turn out to be ambiguously interpreted, thus leading to both under- and misreporting of its true incidence and severity. BIPN is clinically defined as a typical example of a dose-dependent, distally attenuated painful, sensory neuronopathy. Patients pre-treated with neurotoxic regimens and those with pre-existing neuropathy are more likely to develop severe neurotoxicity. To date, there is no effective pharmacological treatment to prevent BIPN, and therefore, interventions remain merely symptomatic to focus on the alleviation of neuropathic pain. Hence, strict adherence to the dose reduction and schedule change algorithm is recommended in order to prevent treatment-emergent BIPN and allow the continuation of treatment. Further studies in animal models and humans, including experimental, clinical, neurophysiological and pharmacogenetic approaches, are needed to allow the identification of the true spectrum of BIPN pathogenesis and characteristics. It is expected that such comprehensive approaches would be the starting point for the development of early preventive and therapeutic interventions against BIPN.Springer Science and Business Media LLC2014info:eu-repo/semantics/articleinfo:eu-repo/semantics/acceptedVersionapplication/pdfhttps://hdl.handle.net/2445/222979Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))reponame:Dipòsit Digital de la UBinstname:Universidad de BarcelonaInglésVersió postprint del document publicat a: https://doi.org/10.1007/s00204-014-1316-5Archives of Toxicology, 2014, vol. 88, num. 9, p. 1669-1679https://doi.org/10.1007/s00204-014-1316-5(c) Springer-Verlag Germany, 2014info:eu-repo/semantics/openAccessoai:diposit.ub.edu:2445/2229792026-05-27T06:46:51Z
dc.title.none.fl_str_mv Bortezomib-induced peripheral neurotoxicity: an update
title Bortezomib-induced peripheral neurotoxicity: an update
spellingShingle Bortezomib-induced peripheral neurotoxicity: an update
Argyriou, Andreas A.
Neuropaties perifèriques
Malalties neurocutànies
Peripheral neuropathies
Neurocutaneous disorders
title_short Bortezomib-induced peripheral neurotoxicity: an update
title_full Bortezomib-induced peripheral neurotoxicity: an update
title_fullStr Bortezomib-induced peripheral neurotoxicity: an update
title_full_unstemmed Bortezomib-induced peripheral neurotoxicity: an update
title_sort Bortezomib-induced peripheral neurotoxicity: an update
dc.creator.none.fl_str_mv Argyriou, Andreas A.
Cavaletti, Guido
Bruna, Jordi
Kyritsis, Athanasios P.
Kalofonos, Haralabos P.
author Argyriou, Andreas A.
author_facet Argyriou, Andreas A.
Cavaletti, Guido
Bruna, Jordi
Kyritsis, Athanasios P.
Kalofonos, Haralabos P.
author_role author
author2 Cavaletti, Guido
Bruna, Jordi
Kyritsis, Athanasios P.
Kalofonos, Haralabos P.
author2_role author
author
author
author
dc.subject.none.fl_str_mv Neuropaties perifèriques
Malalties neurocutànies
Peripheral neuropathies
Neurocutaneous disorders
topic Neuropaties perifèriques
Malalties neurocutànies
Peripheral neuropathies
Neurocutaneous disorders
description This review paper provides a critical exploration of updates concerning the spectrum of characteristics and treatment options of bortezomib-induced peripheral neuropathy (BIPN). Emphasis is given on pathogenesis issues. Although the mechanism underlying BIPN still remains elusive, it is increasingly acknowledged that the inhibition of proteasome activity in dorsal root ganglia and peripheral nerves, the mitochondrial-mediated disruption of Ca++ intracellular homeostasis and the disregulation in nuclear factor kappa B and brain-derived neurotrophic factor play a significant pathogenic role. Assessment of BIPN is based on comprehensive grading scales, using a combination of "subjective" and "objective" parameters, which turn out to be ambiguously interpreted, thus leading to both under- and misreporting of its true incidence and severity. BIPN is clinically defined as a typical example of a dose-dependent, distally attenuated painful, sensory neuronopathy. Patients pre-treated with neurotoxic regimens and those with pre-existing neuropathy are more likely to develop severe neurotoxicity. To date, there is no effective pharmacological treatment to prevent BIPN, and therefore, interventions remain merely symptomatic to focus on the alleviation of neuropathic pain. Hence, strict adherence to the dose reduction and schedule change algorithm is recommended in order to prevent treatment-emergent BIPN and allow the continuation of treatment. Further studies in animal models and humans, including experimental, clinical, neurophysiological and pharmacogenetic approaches, are needed to allow the identification of the true spectrum of BIPN pathogenesis and characteristics. It is expected that such comprehensive approaches would be the starting point for the development of early preventive and therapeutic interventions against BIPN.
publishDate 2014
dc.date.none.fl_str_mv 2014
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/acceptedVersion
format article
status_str acceptedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/222979
url https://hdl.handle.net/2445/222979
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Versió postprint del document publicat a: https://doi.org/10.1007/s00204-014-1316-5
Archives of Toxicology, 2014, vol. 88, num. 9, p. 1669-1679
https://doi.org/10.1007/s00204-014-1316-5
dc.rights.none.fl_str_mv (c) Springer-Verlag Germany, 2014
info:eu-repo/semantics/openAccess
rights_invalid_str_mv (c) Springer-Verlag Germany, 2014
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Springer Science and Business Media LLC
publisher.none.fl_str_mv Springer Science and Business Media LLC
dc.source.none.fl_str_mv Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
reponame:Dipòsit Digital de la UB
instname:Universidad de Barcelona
instname_str Universidad de Barcelona
reponame_str Dipòsit Digital de la UB
collection Dipòsit Digital de la UB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869419826358779904
score 15.811543

Similares en LA Referencia